International Journal of Hematology

, Volume 78, Issue 4, pp 304–311

Current Status of Therapeutic Approaches to Adult T-Cell Leukemia

Progress in hematology

Abstract

More than 2 decades have elapsed since the proposal of adult T-cell leukemia (ATL). Since then, the discovery of the etiologic virus, human T-cell leukemia virus type I (HTLV-I), and the establishment of the diagnostic steps of serum test and molecular study have clearly defined ATL as a distinct disease entity. Because conventional chemotherapy, which is active against other lymphoid malignancies, was proven to be ineffective for treating aggressive forms of ATL,ATL has become the target of several clinical studies for the purpose of improving therapeutic outcomes. Combination chemotherapy exclusively designed for ATL has considerably elevated the treatment response rate in ATL patients, but it has not sufficiently extended the median survival time. The introduction of antiviral agents has led to surprising effects for patients with acute ATL. Monoclonal antibodies seem to be promising, especially for patients with chemotherapy-resistant disease. Unfortunately, these approaches did not prove to be sufficient for most patients with ATL to obtain long-term survival. Recent promising reports on allogeneic stem cell transplantation (allo-SCT) for ATL have suggested that allo-SCT could overcome the limitations that other treatment modalities have not surmounted. More efforts are clearly needed to clarify the usefulness of allo-SCT, especially with reducedintensity conditioning regimens, for ATL patients.

Key words

Adult T-cell leukemia Combination chemotherapy Allogeneic stem cell transplantation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Uchiyama T,Yodoi J, Sagawa K, et al. Adult T-cell leukemia: clinical and hematologic features of 16 cases.Blood. 1977;50:481–492.PubMedGoogle Scholar
  2. 2.
    Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retro-virus from cell lines of human adult T-cell leukemia and its implication in the disease.Proc Natl Acad Sci U S A. 1982;79:2031–2035.PubMedCrossRefGoogle Scholar
  3. 3.
    Eldrich RF, Arnett JA, Williams FM. Global epidemic of human T-cell lymphotropic virus type-1 (HTLV-I).J Emerg Med. 2000;18:109–119.CrossRefGoogle Scholar
  4. 4.
    Tajima K. The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group.Int J Cancer. 1990;45:237–243.PubMedCrossRefGoogle Scholar
  5. 5.
    Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87).Br J Haematol. 1991:79;428–437.PubMedCrossRefGoogle Scholar
  6. 6.
    Kikuchi M, Jaffe ES, Ralfkiaer E. Adult T-cell leukemia/lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds.Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001:200–203.Google Scholar
  7. 7.
    Uchiyama T, Hori T, Tsudo M, et al. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells.J Clin Invest. 1985;76:446–453.PubMedCrossRefGoogle Scholar
  8. 8.
    Hori M, Mitsuhashi S, Kobayashi T, et al. CD30-positive lymphoma in human T-cell leukaemia virus type I carrier without monoclonal integration of HTLV-I.Br J Haematol. 1994;88:419–420.PubMedCrossRefGoogle Scholar
  9. 9.
    Ikeda S, Momita S, Kinoshita K, et al. Clinical course of human T-lymphotropic virus type I carriers with molecularly detectable monoclonal proliferation of T lymphocytes: defining a low- and high-risk population.Blood. 1993;82:2017–2024.PubMedGoogle Scholar
  10. 10.
    Kamihira S, Atogami S, Sohda H, et al. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia.Cancer. 1994;73:2753–2758.PubMedCrossRefGoogle Scholar
  11. 11.
    Shirono K, Hattori T, Takatsuki K. A new classification of clinical stages of adult T-cell leukemia based on prognosis of the disease.Leukemia. 1994;8:1834–1837.PubMedGoogle Scholar
  12. 12.
    Tsukasaki K, Imaizumi Y, Tawara M, et al. Diversity of leukaemic cell morphology in ATL correlates with prognostic factors, aberrant immunophenotype and defective HTLV-I genotype.Br J Haematol. 1999;105:369–375.PubMedCrossRefGoogle Scholar
  13. 13.
    Sadamori N, Ichiba M, Mine M, et al. Clinical significance of serum thymidine kinase in adult T-cell leukaemia and acute myeloid leukaemia.Br J Haematol. 1995;90:100–105.PubMedCrossRefGoogle Scholar
  14. 14.
    Ikeda K, Oka M, Yamada Y, et al. Adult T-cell leukemia cells overexpress the multidrug-resistance-protein (MRP) and lung-resistance-protein (LRP) genes.Int J Cancer. 1999;82:599–604.PubMedCrossRefGoogle Scholar
  15. 15.
    Ohno N, Tani A, Uozumi K, et al. Expression of functional lung resistance-related protein predicts poor outcome in adult T-cell leukemia.Blood. 2001;98:1160–1165.PubMedCrossRefGoogle Scholar
  16. 16.
    Ohno N, Tani A, Chen ZS, et al. Prognostic significance of multidrug resistance protein in adult T-cell leukemia.Clin Cancer Res. 2001;7:3120–3126.PubMedGoogle Scholar
  17. 17.
    Baba Y, Arakawa A, Furusawa M, et al. Radiation therapy of adult T-cell leukemia.Acta Oncol. 1994;33:667–670.PubMedCrossRefGoogle Scholar
  18. 18.
    Kawano F, Yamaguchi K, Nishimura H, et al. Variation in the clinical courses of adult T-cell leukemia.Cancer. 1985;55:851–856.PubMedCrossRefGoogle Scholar
  19. 19.
    Motoi T, Uchiyama T, Uchino H, et al. Serum soluble interleukin-2 receptor levels in patients with adult T-cell leukemia and human T-cell leukemia/lymphoma virus type-I seropositive healthy carriers.Jpn J Cancer Res. 1988;79:593–599.PubMedGoogle Scholar
  20. 20.
    Shimoyama M, Ota K, Kikuchi M, et al. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia.J Clin Oncol. 1988;6:1088–1097.PubMedGoogle Scholar
  21. 21.
    Tsukasaki K, Ikeda S, Murata K, et al. Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphoma.Leuk Res. 1993;17:157–166.PubMedCrossRefGoogle Scholar
  22. 22.
    Uozumi K, Hanada S, Ohno N, et al. Combination chemotherapy (RCM protocol: response-oriented cyclic multidrug protocol) for the acute or lymphoma type adult T-cell leukemia.Leuk Lymphoma. 1995;18:317–323.PubMedCrossRefGoogle Scholar
  23. 23.
    Matsushita K, Matsumoto T, Ohtsubo H, et al. Long-term maintenance combination chemotherapy with OPEC/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia/lymphoma.Leuk Lymphoma. 1999;36:67–75.PubMedCrossRefGoogle Scholar
  24. 24.
    Taguchi H, Kinoshita KI, Takatsuki K, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support.J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:182–186.PubMedGoogle Scholar
  25. 25.
    Uozumi K, Nakahara K, Takatsuka Y, et al. Granulocyte colonystimulating factor in the combination chemotherapy for adult T-cell leukemia (ATL).Leuk Lymphoma. 1998;29:407–414.PubMedCrossRefGoogle Scholar
  26. 26.
    Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemialymphoma: Japan Clinical Oncology Group Study 9303.Br J Haematol. 2001;113:375–382.PubMedCrossRefGoogle Scholar
  27. 27.
    Daenen S, Rojer RA, Smit JW, et al. Successful chemotherapy with deoxycoformycin in adult T-cell lymphoma-leukaemia.Br J Haematol. 1984;58:723–727.PubMedCrossRefGoogle Scholar
  28. 28.
    Tobinai K, Shimoyama M, Inoue S, et al. Phase I study of YK-176 (2′-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma. The DCF Study Group.Jpn J Clin Oncol. 1992;22:164–171.PubMedGoogle Scholar
  29. 29.
    Lofters W, Campbell M, Gibbs WN, et al. 2′-Deoxycoformycin therapy in adult T-cell leukemia/lymphoma.Cancer. 1987;60:2605–2608.PubMedCrossRefGoogle Scholar
  30. 30.
    Yamaguchi K, Yul LS, Oda T, et al. Clinical consequences of 2′-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia.Leuk Res. 1986;10:989–993.PubMedCrossRefGoogle Scholar
  31. 31.
    Tsukasaki K, Tobinai K, Shimoyama M, et al. Deoxycoformycincontaining combination chemotherapy for adult T-cell leukemialymphoma: Japan Clinical Oncology Group Study (JCOG9109).Int J Hematol. 2003;77:164–170.PubMedCrossRefGoogle Scholar
  32. 32.
    Tobinai K, Uike N, Saburi Y, et al. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma.Int J Hematol. 2003;77:512–517.PubMedCrossRefGoogle Scholar
  33. 33.
    Tsuda H, Takatsuki K, Ohno R, et al. Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy.Br J Cancer. 1994;70:771–774.PubMedGoogle Scholar
  34. 34.
    Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma.N Engl J Med. 1995;333:1540–1545.PubMedCrossRefGoogle Scholar
  35. 35.
    Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.N Engl J Med. 1996;335:91–97.PubMedCrossRefGoogle Scholar
  36. 36.
    Tsukasaki K, Maeda T, Arimura K, et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature.Bone Marrow Transplant. 1999;23:87–89.PubMedCrossRefGoogle Scholar
  37. 37.
    Watanabe J, Kondo H, Hatake K. Autologous stem cell transplantations for recurrent adult T cell leukaemia/lymphoma using highly purified CD34+ cells derived from cryopreserved peripheral blood stem cells.Leuk Lymphoma. 2001;42:1115–1117.PubMedCrossRefGoogle Scholar
  38. 38.
    Fujiwara H, Arima N, Akasaki Y, et al. Interferon-alpha therapy following autologous peripheral blood stem cell transplantation for adult T cell leukemia/lymphoma.Acta Haematol. 2002;107:213–219.PubMedCrossRefGoogle Scholar
  39. 39.
    Hermine O, Bouscary D, Gessain A, et al. Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa.N Engl J Med. 1995;332:1749–1751.PubMedCrossRefGoogle Scholar
  40. 40.
    Gill PS, Harrington W Jr, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine.N Engl J Med. 1995;332:1744–1748.PubMedCrossRefGoogle Scholar
  41. 41.
    Matutes E, Taylor GP, Cavenagh J, et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients.Br J Haematol. 2001;113:779–784.PubMedCrossRefGoogle Scholar
  42. 42.
    White JD, Wharfe G, Stewart DM, et al. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma.Leuk Lymphoma. 2001;40:287–294.PubMedCrossRefGoogle Scholar
  43. 43.
    Bazarbachi A, Hermine O. Treatment of adult T-cell leukaemia/ lymphoma: current strategy and future perspectives.Virus Res. 2001;78:79–92.PubMedCrossRefGoogle Scholar
  44. 44.
    Tosi P, Visani G, Ottaviani E, et al. Synergistic cytotoxicity of AZT plus alpha and gamma interferon in chronic myeloid leukemia cell line K562.Eur J Haematol. 1993;51:209–213.PubMedCrossRefGoogle Scholar
  45. 45.
    Bazarbachi A, Nasr R, El-Sabban ME, et al. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma.Leukemia. 2000;14:716–721.PubMedCrossRefGoogle Scholar
  46. 46.
    Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia.Blood. 1993;82:1701–1712.PubMedGoogle Scholar
  47. 47.
    Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac.Blood. 1995;86:4063–4075.PubMedGoogle Scholar
  48. 48.
    Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.J Clin Oncol. 2000;18:1622–1636.PubMedGoogle Scholar
  49. 49.
    Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies.Med Oncol. 2002;19:S27-S32.PubMedCrossRefGoogle Scholar
  50. 50.
    Tajima K. The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group.Int J Cancer. 1990;45:237–243.PubMedCrossRefGoogle Scholar
  51. 51.
    Sobue R, Yamauchim T, Miyamura K, et al. Treatment of adult T cell leukemia with mega-dose cyclophosphamide and total body irradiation followed by allogeneic bone marrow transplantation.Bone Marrow Transplant. 1987;4:441–444.Google Scholar
  52. 52.
    Ljungman P, Lawler M, Asjo B, et al. Infection of donor lymphocytes with human T lymphotrophic virus type I (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia.Br J Haematol. 1994;88:403–405.PubMedCrossRefGoogle Scholar
  53. 53.
    Stockerl-Goldstein KE, Blume KG. A decade of progress in allogeneic hematopoietic cell transplantation: 1990-2000.Adv Cancer Res. 2001;81:1–59.PubMedCrossRefGoogle Scholar
  54. 54.
    Appelbaum FR. Haematopoietic cell transplantation as immunotherapy.Nature. 2001;411:385–389.PubMedCrossRefGoogle Scholar
  55. 55.
    Borg A, Yin JA, Johnson PR, et al. Successful treatment of HTLV-Iassociated acute adult T-cell leukaemia lymphoma by allogeneic bone marrow transplantation.Br J Haematol. 1996;94:713–715.PubMedCrossRefGoogle Scholar
  56. 56.
    Leclercq I, Mortreux F, Morschhauser F, et al. Semiquantitative analysis of residual disease in patients treated for adult T-cell leukaemia/lymphoma (ATLL).Br J Haematol. 1999;105:743–751.PubMedCrossRefGoogle Scholar
  57. 57.
    Obama K, Tara M, Sao H, et al. Allogenic bone marrow transplantation as a treatment for adult T-cell leukemia.Int J Hematol. 1999;69:203–205.PubMedGoogle Scholar
  58. 58.
    Tajima K, Amakawa R, Uehira K, et al. Adult T-cell leukemia successfully treated with allogeneic bone marrow transplantation.Int J Hematol. 2000;71:290–293.PubMedGoogle Scholar
  59. 59.
    Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation.Bone Marrow Transplant. 2001;27:15–20.PubMedCrossRefGoogle Scholar
  60. 60.
    Ogata M, Ogata Y, Imamura T, et al. Successful bone marrow transplantation from an unrelated donor in a patient with adult T cell leukemia.Bone Marrow Transplant. 2002;30:699–701.PubMedCrossRefGoogle Scholar
  61. 61.
    Kami M, Hamaki T, Miyakoshi S, et al. Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma.Br J Haematol. 2003;120:304–309.PubMedCrossRefGoogle Scholar
  62. 62.
    Ohguchi H, Sai T, Hamazaki Y, et al. Cyclosporin A withdrawal causes spontaneous remission of recurrent subcutaneous tumors after allogeneic peripheral blood stem cell transplantation for adult T-cell leukemia/lymphoma [in Japanese].Rinsho Ketsueki. 2003;44:102–107.PubMedGoogle Scholar
  63. 63.
    Ishikawa T, Ichinohe T, Imada K, et al. Allogeneic hematopoietic stem cell transplantation for ATL. In: Kazuo Sugamura, ed.Gann Monograph on Cancer Research: Two Decades of Adult T-Cell Leukemia and HTLV-I Research; Progress in Basic Research and Its Applications in Clinical Advances,No 50. Tokyo: Japan Scientific Press; 2003:253–262.Google Scholar
  64. 64.
    Emmanouilides CE, Territo M. HTLV-I-associated myelopathy following allogeneic bone marrow transplantation.Bone Marrow Transplant. 1999;24:205–206.PubMedCrossRefGoogle Scholar
  65. 65.
    Du W, Dansey R, Abella EM, et al. Successful allogeneic bone marrow transplantation in selected patients over 50 years of age-a single institution’s experience.Bone Marrow Transplant. 1998;21:1043–1047.PubMedCrossRefGoogle Scholar
  66. 66.
    Hirose K, Tajima K. The 8th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan:The T- and B-cell Malignancy Study Group [in Japanese].Gann no Rinsyou. 1998;44:381–397.Google Scholar
  67. 67.
    Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.Blood. 1997;89:4531–4536.PubMedGoogle Scholar
  68. 68.
    Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.Blood. 1998;91:756–763.PubMedGoogle Scholar
  69. 69.
    Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.J Clin Oncol. 1998;16:2817–2824.PubMedGoogle Scholar
  70. 70.
    Abe Y, Yashiki S, Choi I, et al. Eradication of virus-infected T-cells in a case of adult T-cell leukemia/lymphoma by nonmyeloablative peripheral blood stem cell transplantation with conditioning consisting of low-dose total body irradiation and pentostatin.Int J Hematol. 2002;76:91–93.PubMedCrossRefGoogle Scholar
  71. 71.
    Platzbecker U, Ehninger G, Schmitz N, et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases.Ann Hematol. 2003;82:463–468.PubMedCrossRefGoogle Scholar
  72. 72.
    Nasr R, Rosenwald A, El-Sabban ME, et al. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-I-infected leukemic cells.Blood. 2003;101:4576–4582.PubMedCrossRefGoogle Scholar
  73. 73.
    Mori N, Yamada Y, Ikeda S, et al. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells.Blood. 2002;100:1828–1834.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2003

Authors and Affiliations

  1. 1.Department of Hematology/OncologyGraduate School of Medicine, Kyoto UniversityKyotoJapan

Personalised recommendations